Patients with advanced kidney cancer are being recruited for participation in a research study involving an experimental drug

IRB/UVA Tracking #
20262
Principal Investigator
Robert Dreicer
Contact
Milos Lesevic
Contact Phone
434.243.0544
Official Trial Title
Phase II Randomized Double Blind Trial of PF-04518600, an OX40 Antibody, in Combination with Axitinib versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients with Metastatic Renal Cell Carcinoma
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for adults ages 18 and over and who have advanced kidney cancer that was previously treated with immunotherapy but has now progressed. The purpose of this study is to see whether taking an investigational drug (called PF-04518600) in addition to chemotherapy results in a better outcome for subjects with advanced kidney cancer. Participants will be randomly selected to one of two treatment groups: to receive chemotherapy and study medication (PF-04518600) or to receive chemotherapy and a placebo (a substance that has no effect but looks like PF-04518600.) The safety and side effects of the experimental drug in combination with chemotherapy will also be reviewed for this study.

Participation is approximately 6-9 months. This includes screening, treatment, and follow-up periods. Study specific tests will be provided at no cost to you.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT03092856

Compensation

NA